Page 27 - 中国全科医学2022-11

·1304· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

［17］CASANOVA C，GONZALEZ-DÁVILA E，MARTÍNEZ- for chronic respiratory disease［J］. Cochrane Database Syst Rev，
GONZALEZ C，et al. Natural course of the diffusing capacity 2021，1（1）：CD013040. DOI：10.1002/14651858.CD013040.
of the lungs for carbon monoxide in COPD：importance of pub2.
sex［J］. Chest，2021，160（2）：481-490. DOI：10.1016/j. ［30］LIU X，FU C P，HU W P，et al. The effect of Tai Chi on the
chest.2021.03.069. pulmonary rehabilitation of chronic obstructive pulmonary disease：
［18］CELLI B R，ANDERSON J A，COWANS N J，et al. a systematic review and meta-analysis［J］. Ann Palliat Med，
Pharmacotherapy and lung function decline in patients with chronic 2021，10（4）：3763-3782. DOI：10.21037/apm-20-940.
obstructive pulmonary disease. A systematic review［J］. Am ［31］GOUZI F，MAURY J，HÉRAUD N，et al. Additional effects of
J Respir Crit Care Med，2021，203（6）：689-698. DOI： nutritional antioxidant supplementation on peripheral muscle during
10.1164/rccm.202005-1854OC. pulmonary rehabilitation in COPD patients：a randomized controlled
［19］JENKINS C R，WEN F Q，MARTIN A，et al. The effect of trial［J］. Oxid Med Cell Longev，2019，2019：5496346. DOI：
low-dose corticosteroids and theophylline on the risk of acute 10.1155/2019/5496346.
exacerbations of COPD：the TASCS randomised controlled ［32］VAN BEERS M，RUTTEN-VAN MÖLKEN M P M H，VAN DE
trial［J］. Eur Respir J，2021，57（6）：2003338. DOI： BOOL C，et al. Clinical outcome and cost-effectiveness of a 1-year
10.1183/13993003.03338-2020.
nutritional intervention programme in COPD patients with low muscle
［20］中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协 mass：the randomized controlled NUTRAIN trial［J］. Clin Nutr，
会呼吸医师分会慢性阻塞性肺疾病工作委员会 . 慢性阻塞性肺
2020，39（2）：405-413. DOI：10.1016/j.clnu.2019.03.001.
疾病诊治指南（2021 年修订版）［J］. 中华结核和呼吸杂志，
［33］BAFADHEL M，MCKENNA S，AGBETILE J，et al.
2021，44（3）：170-205.
Aspergillus fumigatus during stable state and exacerbations of
［21］慢性阻塞性肺疾病糖皮质激素规范管理撰写组 . 慢性阻塞性肺
COPD［J］. Eur Respir J，2014，43（1）：64-71. DOI：
疾病糖皮质激素规范管理专家共识（2021 版）［J］. 中华结核
10.1183/09031936.00162912.
和呼吸杂志，2021，44（12）：1054-1063.
［34］HUERTA A，SOLER N，ESPERATTI M，et al. Importance of
［22］TAN W C，BOURBEAU J，NADEAU G，et al. High eosinophil
Aspergillus spp. isolation in acute exacerbations of severe COPD：
counts predict decline in FEV 1 ：results from the CanCOLD
prevalence，factors and follow-up：the FUNGI-COPD study
study［J］. Eur Respir J，2021，57（5）：2000838. DOI：
［J］. Respir Res，2014，15（1）：17. DOI：10.1186/1465-
10.1183/13993003.00838-2020.
9921-15-17.
［23］PARK H Y，CHANG Y，KANG D，et al. Blood eosinophil counts
［35］BULPA P，DUPLAQUET F，DIMOPOULOS G，et al. Invasive
and the development of obstructive lung disease：the Kangbuk
pulmonary aspergillosis in chronic obstructive pulmonary disease
Samsung Health Study［J］. Eur Respir J，2021，58（4）：
exacerbations［J］. Semin Respir Crit Care Med，2020，41（6）：
2003823. DOI：10.1183/13993003.03823-2020.
851-861. DOI：10.1055/s-0040-1702210.
［24］LIPSON D A，CRIM C，CRINER G J，et al. Reduction in all-
［36］GU Y，YE X P，LIU Y X，et al. A risk-predictive model for
cause mortality with fluticasone furoate/umeclidinium/vilanterol in
invasive pulmonary aspergillosis in patients with acute exacerbation
patients with chronic obstructive pulmonary disease［J］. Am J
of chronic obstructive pulmonary disease［J］. Respir Res，2021，
Respir Crit Care Med，2020，201（12）：1508-1516. DOI：
22：176.
10.1164/rccm.201911-2207OC.
［37］COUTURAUD F，BERTOLETTI L，PASTRE J，et al. Prevalence
［25］MARTINEZ F J，RABE K F，FERGUSON G T，et al.
of pulmonary embolism among patients with COPD hospitalized with
Reduced all-cause mortality in the ETHOS trial of budesonide/
acutely worsening respiratory symptoms［J］. JAMA，2021，325
glycopyrrolate/formoterol for chronic obstructive pulmonary disease.
（1）：59-68. DOI：10.1001/jama.2020.23567.
A randomized，double-blind，multicenter，parallel-group
study［J］. Am J Respir Crit Care Med，2021，203（5）：553- ［38］FU C P，LIU X，ZHU Q Q，et al. Efficiency of high-flow nasal
564. DOI：10.1164/rccm.202006-2618OC. Cannula on pulmonary rehabilitation in COPD patients：a meta-
［26］FRANCIOSI A N，HOBBS B D，MCELVANEY O J，et al. analysis［J］. Biomed Res Int，2020，2020：7097243. DOI：
Clarifying the risk of lung disease in SZ alpha-1 antitrypsin 10.1155/2020/7097243.
deficiency［J］. Am J Respir Crit Care Med，2020，202（1）： ［39］ALSALLAKH M A，SIVAKUMARAN S，KENNEDY S，
73-82. DOI：10.1164/rccm.202002-0262OC. et al. Impact of COVID-19 lockdown on the incidence and
［27］LINDENAUER P K，STEFAN M S，PEKOW P S，et al. mortality of acute exacerbations of chronic obstructive pulmonary
Association between initiation of pulmonary rehabilitation after disease：national interrupted time series analyses for Scotland
hospitalization for COPD and 1-year survival among medicare and Wales［J］. BMC Med，2021，19（1）：124. DOI：
beneficiaries［J］. JAMA，2020，323（18）：1813-1823. 10.1186/s12916-021-02000-w.
DOI：10.1001/jama.2020.4437. ［40］CHAN K P F，MA T F，KWOK W C，et al. Significant reduction
［28］STONE P W，HICKMAN K，STEINER M C，et al. Predictors in hospital admissions for acute exacerbation of chronic obstructive
of pulmonary rehabilitation completion in the UK［J］. pulmonary disease in Hong Kong during coronavirus disease 2019
ERJ Open Res，2021，7（1）：00509-02020. DOI： pandemic［J］. Respir Med，2020，171：106085. DOI：
10.1183/23120541.00509-2020. 10.1016/j.rmed.2020.106085.
［29］COX N S，DAL CORSO S，HANSEN H，et al. Telerehabilitation （下转第1308页）